05/18/22 7:00 AMNasdaq : IMTX Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid TumorsThe Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab 1, a PD-1 immune checkpoint inhibitor, in patients with multiple solid tumors Initiation of the combination treatment followsRHEA-AIneutral
05/10/22 7:00 AMNasdaq : IMTX clinical trialImmatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid TumorsPatient enrollment for IMA401 Phase 1 trial started at first clinical site in Germany The study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent and/or refractory solid tumors TCER® IMA401 targets MAGEA4/8 and will be developed inRHEA-AIvery positive
03/23/22 7:00 AMNasdaq : IMTX earningsImmatics Announces Full Year 2021 Financial Results and Corporate UpdateIMA203 TCR-T candidate targeting PRAME demonstrated a 50 % objective response rate across different solid tumor types in an interim update of Phase 1a dose escalation M ultiple IMA203 Ph ase 1b expansion cohorts being initiated in Q2 2022 including monotherapy at target dose level , checkpointRHEA-AIneutral
02/04/22 6:59 AMNYSE, Nasdaq : BMY, IPSC, IMTX earningsADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021Bristol Myers Squibb today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’ s pipeline that further progressed the company’ s portfolio renewal. “I am proud of how our company performed in 2021, helping more patients across our...RHEA-AIneutral
02/04/22 6:59 AMNYSE, Nasdaq : BMY, IPSC, IMTX earningsBristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021Bristol Myers Squibb today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’ s pipeline that further progressed the company’ s portfolio renewal. “I am proud of how our company performed in 2021, helping more patients across our...RHEA-AIneutral
12/14/21 6:59 AMNYSE, Nasdaq : BMY, IMTX Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US Immatics to receive upfront payment of $150 million and additional milestone payments of up to $770 million plus tiered double-digit royalties on net...RHEA-AIpositive
12/14/21 6:59 AMNasdaq : IMTX Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US Immatics to receive upfront payment of $150 million and additional milestone payments of up to $770RHEA-AIpositive
11/16/21 7:00 AMNasdaq : IMTX earningsImmatics Announces Third Quarter 2021 Financial Results and Provides Business UpdateInterim data update at SITC for ongoing ACTe ngine ® IMA203 trial targeting PRAME demonstrated clinical responses a cross multiple solid tumor types during dose escalation phase Immatics to i nitiate three expansion cohorts for IMA203 targeting PRAME : monotherapy, combination with checkpointRHEA-AIneutral
11/09/21 8:00 AMNasdaq : IMTX clinical trialImmatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAMECompany to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across multiple solid cancerRHEA-AIneutral
11/01/21 8:00 AMNasdaq : IMTX conferencesImmatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company will provide an update on itsRHEA-AIneutral